Interferon γ limits the effectiveness of melanoma peptide vaccines

Area of Science:

• Immunology
• Cancer Research
• Vaccinology

Background:

• Generating tumor-reactive cytotoxic T lymphocytes (CTLs) via therapeutic vaccines is crucial for cancer treatment.
• Existing vaccines often fail to eradicate established tumors due to low CTL numbers and immunosuppressive tumor microenvironments.

Purpose of the Study:

• To design a peptide vaccine capable of generating substantial tumor-reactive CTLs in a melanoma mouse model.
• To investigate the impact of interferon-gamma (IFNγ) on vaccine-induced CTL responses and anti-tumor efficacy.

Main Methods:

• Development of a novel peptide vaccine for melanoma.
• Administration of the vaccine in a mouse model.
• Assessment of CTL generation, tumor recognition, and anti-tumor effects.
• Analysis of tumor cell surface molecule expression, including MHC class I, in response to IFNγ.

Main Results:

• The peptide vaccine successfully generated large numbers of tumor-reactive CTLs.
• IFNγ unexpectedly decreased CTL tumor recognition and anti-tumor activity.
• Tumors exposed to IFNγ upregulated noncognate MHC class I molecules, impairing T-cell activation.
• Vaccine efficacy was restored when IFNγ's inhibitory effects were mitigated.

Conclusions:

• Peptide vaccines can induce potent anti-tumor CTL responses.
• IFNγ can paradoxically inhibit vaccine-mediated tumor eradication by promoting tumor immune evasion through MHC class I upregulation.
• Targeting or curtailing inhibitory IFNγ activities may be essential for achieving complete tumor eradication with peptide vaccines.